Illumina to Acquire SomaLogic for $350 Million, Expanding into Proteomics and Precision Medicine

Illumina, Inc. (NASDAQ:ILMN) is one of the top 10 healthcare AI stocks to buy according to hedge funds.

Illumina, Inc. (NASDAQ:ILMN) announced recently that it has entered into a definitive agreement with Standard BioTools (NASDAQ:LAB) to acquire SomaLogic, a recognized leader in proteomics technology, for $350 million in cash at closing, along with up to $75 million in performance-based milestones and royalties. The deal includes the acquisition of SomaLogic’s proprietary proteomics platform and other specified assets, further strengthening Illumina’s position in multi-omic analysis and precision medicine.

Illumina to Acquire SomaLogic for $350 Million, Expanding into Proteomics and Precision Medicine

A research facility with medical professionals surrounded by diagnostic equipment.

SomaLogic’s platform enables high-throughput protein measurement and analysis, a critical advancement in understanding human biology at scale. By integrating these capabilities, Illumina aims to expand its clinical and research offerings into the proteomics space, complementing its core strength in genomics. This combination will provide researchers and clinicians with deeper biological insights, facilitating more informed decisions in drug development, diagnostics, and disease monitoring. The transaction is expected to close later this year, pending regulatory approvals and customary closing conditions.

As a long-time pioneer in genetic sequencing, Illumina, Inc. (NASDAQ:ILMN) continues to evolve into a broader healthcare technology company. The company has increasingly embraced artificial intelligence and machine learning to analyze complex biological data. These capabilities allow for more accurate predictions in clinical outcomes and therapeutic response, positioning Illumina as an emerging leader in healthcare AI. This acquisition marks a strategic step forward, giving Illumina the tools to integrate genomic and proteomic data at scale, an essential move toward enabling truly personalized medicine.

While we acknowledge the potential of ILMN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ILMN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now.

Disclosure: None.